Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GHZ339 in Moderate to Severe Atopic Dermatitis
NCT06947993Phase 2Recruiting
- Sponsor
- Novartis
- Start
- May 2025
- Primary completion
- Nov 2028
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of GHZ339 in atopic dermatitis (AD) (5 arms), sponsored by Novartis. Primary endpoint: Eczema Area and Severity Index at 16 weeks. Started May 2025; status: recruiting.
02
Drugs
GHZ339
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06947993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947993.